TENLIFAST-M 500SR / 1000SR Tablets

Description

Diabetes is not just high blood sugar, it means; 

> Risk of stroke

> Visual disturbance

> Risk of heart disease

> High blood pressure

> Nerve damage

> Foot problem

• Possess insulinotropic & glucagonostatic effects that control blood glucose for 24 hours. 
• Safe combination for patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy.

Teneligliptin

• Exhibits long-lasting & more potent inhibition of the DPP-4 enzyme than sitagliptin, vildagliptin, and alogliptin. 

• Ensures stabilization of glucose fluctuations throughout the day owing to its long half-life.

• Imparts sustained effects on glycemic control, thereby reducing the complications of hypoglycemia and weight gain.

• Safe for patients with renal or liver impairment.

Metformin

• Improves glucose tolerance in patients with type-2 diabetes, lowering both basal and postprandial plasma glucose.

• Positively affect lipid profiles, and improve vascular and hemodynamic indices.

Combination

• Teneligliptin when used as part of dual therapy with metformin leads to significant Glycated Haemoglobin (HbA1c) reduction of 1.07% which incidentally is slightly better compared with phase III trials conducted for the same combination in the Korean population (HbA1c reduction of 0.87% compared to baseline at 16 weeks).
• Teneligliptin as an add-on to metformin plus sulfonylurea therapy showed a significant (P-value <0.0001) reduction in HbA1c, fasting plasma glucose, and postprandial plasma glucose.
• While 43.96% of patients receiving teneligliptin + metformin and 35.03% of patients receiving teneligliptin + metformin + sulfonylurea achieved the same target.